These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 24557576)
21. Improved posttransplant mortality after share 35 for liver transplantation. Kwong AJ; Goel A; Mannalithara A; Kim WR Hepatology; 2018 Jan; 67(1):273-281. PubMed ID: 28586179 [TBL] [Abstract][Full Text] [Related]
22. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. Sharma P; Schaubel DE; Gong Q; Guidinger M; Merion RM Hepatology; 2012 Jan; 55(1):192-8. PubMed ID: 21898487 [TBL] [Abstract][Full Text] [Related]
23. Impact of MELD-based allocation on end-stage renal disease after liver transplantation. Sharma P; Schaubel DE; Guidinger MK; Goodrich NP; Ojo AO; Merion RM Am J Transplant; 2011 Nov; 11(11):2372-8. PubMed ID: 21883908 [TBL] [Abstract][Full Text] [Related]
24. Hepatopulmonary Syndrome and Portopulmonary Hypertension: Management in Liver Transplantation in the Horizon 2020. Sendra C; Carballo-Rubio V; Sousa JM Transplant Proc; 2020 Jun; 52(5):1503-1506. PubMed ID: 32278579 [TBL] [Abstract][Full Text] [Related]
25. MELD exception for liver transplantation in portopulmonary hypertension: current implementation and future considerations. Porres-Aguilar M; Bartolome SD; Duarte-Rojo A Ann Hepatol; 2014; 13(6):719-21. PubMed ID: 25332257 [No Abstract] [Full Text] [Related]
26. Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: Risk modulated by model for end-stage liver disease. Bambha KM; Dodge JL; Gralla J; Sprague D; Biggins SW Liver Transpl; 2015 Oct; 21(10):1286-94. PubMed ID: 26097202 [TBL] [Abstract][Full Text] [Related]
27. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score. Kwong AJ; Lai JC; Dodge JL; Roberts JP Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624 [TBL] [Abstract][Full Text] [Related]
29. Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Meta-Analysis. Deroo R; Trépo E; Holvoet T; De Pauw M; Geerts A; Verhelst X; Colle I; Van Vlierberghe H; Fallon MB; Raevens S Hepatology; 2020 Nov; 72(5):1701-1716. PubMed ID: 32017176 [TBL] [Abstract][Full Text] [Related]
30. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry. Taniguchi M Clin Transpl; 2012; ():41-65. PubMed ID: 23721009 [TBL] [Abstract][Full Text] [Related]
31. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Sharpton SR; Feng S; Hameed B; Yao F; Lai JC Transplantation; 2014 Sep; 98(5):557-62. PubMed ID: 24717221 [TBL] [Abstract][Full Text] [Related]
32. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284 [TBL] [Abstract][Full Text] [Related]
34. The impact of MELD exception points for hydrothorax on posttransplant mortality: a propensity score-matched analysis. Fathma S; Boateng S; Amatya A; Ameyaw P; Banini BA Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1016-1021. PubMed ID: 38829948 [TBL] [Abstract][Full Text] [Related]
35. Liver Transplant Survival Index for Patients with Model for End-Stage Liver Disease Score ≥ 35: Modeling Risk and Adjusting Expectations in the Share 35 Era. Steggerda JA; Kim IK; Todo T; Malinoski D; Klein AS; Bloom MB J Am Coll Surg; 2019 Apr; 228(4):437-450.e8. PubMed ID: 30594593 [TBL] [Abstract][Full Text] [Related]
36. Portopulmonary hypertension. Lv Y; Han G; Fan D Scand J Gastroenterol; 2016 Jul; 51(7):795-806. PubMed ID: 27002212 [TBL] [Abstract][Full Text] [Related]
37. Portopulmonary Hypertension in Nontransplanted Patients: Results of the Largest US Single-Institution Registry. Cajigas HR; Burger CD; Cartin-Ceba R; DuBrock H; Swanson K; Vargas HE; Keaveny AP; Watt KD; Krowka M Mayo Clin Proc; 2022 Dec; 97(12):2236-2247. PubMed ID: 36336515 [TBL] [Abstract][Full Text] [Related]
38. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562 [TBL] [Abstract][Full Text] [Related]
39. Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States. Sawinski D; Goldberg DS; Blumberg E; Abt PL; Bloom RD; Forde KA Clin Infect Dis; 2015 Oct; 61(7):1054-62. PubMed ID: 26082506 [TBL] [Abstract][Full Text] [Related]
40. Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area. Chok KS; Fung JY; Chan AC; Dai WC; Sharr WW; Cheung TT; Chan SC; Lo CM Ann Surg; 2017 Jan; 265(1):173-177. PubMed ID: 28009743 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]